A Test in Focus Archives - Insights

Reflex Test Guides Precise Care for Arsenic Exposure: Paul Jannetto, Ph.D.

Barbara J. Toman — Tue, 15 Apr 2025 13:00:00 +0000

Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.

The post Reflex Test Guides Precise Care for Arsenic Exposure: Paul Jannetto, Ph.D. appeared first on Insights.

Comprehensive Genetic Test Guides Prescribing of a Transplant Anti-Rejection Drug: Jessica Wright, Pharm.D., BCACP

Barbara J. Toman — Tue, 08 Apr 2025 13:00:00 +0000

Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.

The post Comprehensive Genetic Test Guides Prescribing of a Transplant Anti-Rejection Drug: Jessica Wright, Pharm.D., BCACP appeared first on Insights.

Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D.

Barbara J. Toman — Tue, 21 Jan 2025 14:00:00 +0000

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.

The post Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D. appeared first on Insights.

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

Barbara J. Toman — Tue, 24 Sep 2024 13:00:00 +0000

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

The post Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC appeared first on Insights.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

Barbara J. Toman — Tue, 17 Sep 2024 13:00:00 +0000

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

The post Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S. appeared first on Insights.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

Barbara J. Toman — Tue, 10 Sep 2024 13:00:00 +0000

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

The post Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D. appeared first on Insights.

Panel Boosts Therapeutic Monitoring of IBD Drug: Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D.

Barbara J. Toman — Tue, 06 Aug 2024 13:00:00 +0000

Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of patients with inflammatory bowel disease.

The post Panel Boosts Therapeutic Monitoring of IBD Drug: Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D. appeared first on Insights.

Updates Streamline Autoimmune Neurology Testing: Anastasia Zekeridou, M.D., Ph.D.

Barbara J. Toman — Tue, 11 Jun 2024 13:00:00 +0000

Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.

The post Updates Streamline Autoimmune Neurology Testing: Anastasia Zekeridou, M.D., Ph.D. appeared first on Insights.

Tests Aid Diagnosis of Cancer-Associated Neurological Disorders: Divyanshu Dubey, M.B.B.S.

Barbara J. Toman — Tue, 04 Jun 2024 13:00:00 +0000

Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing disabling neurological symptoms and malignancy.

The post Tests Aid Diagnosis of Cancer-Associated Neurological Disorders: Divyanshu Dubey, M.B.B.S. appeared first on Insights.

New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D.

Barbara J. Toman — Tue, 14 May 2024 13:00:00 +0000

Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test help pinpoint diagnosis, to guide prognosis and treatment decisions.

The post New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D. appeared first on Insights.